Moreover, increasing evidence suggests that cancers that initially respond to EGFR may subsequently become refractory, with a central role being played by human epidermal growth factor receptor (HER) family members (HER2 or erbB2, HER3 or erbB3, HER4 or erbB4)10. This evidence concerns the gene ERBB2 and cancer.